180 related articles for article (PubMed ID: 32006671)
21. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
[No Abstract] [Full Text] [Related]
22. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
23. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
24. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
Schreiber S; Yamamoto K; Muniz R; Iwura T
Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
[TBL] [Abstract][Full Text] [Related]
25. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
27. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
28. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
Liu J; Eris T; Li C; Cao S; Kuhns S
BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
[TBL] [Abstract][Full Text] [Related]
29. Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?
Tu CL; Wang YL; Hu TM; Hsu LF
BioDrugs; 2019 Aug; 33(4):437-446. PubMed ID: 31111423
[TBL] [Abstract][Full Text] [Related]
30. A Data Driven Approach to Support Tailored Clinical Programs for Biosimilar Monoclonal Antibodies.
Guillen E; Ekman N; Barry S; Weise M; Wolff-Holz E
Clin Pharmacol Ther; 2023 Jan; 113(1):108-123. PubMed ID: 36546547
[TBL] [Abstract][Full Text] [Related]
31. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
[TBL] [Abstract][Full Text] [Related]
32. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G
MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198
[TBL] [Abstract][Full Text] [Related]
34. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
[TBL] [Abstract][Full Text] [Related]
35. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars.
Millán-Martín S; Jakes C; Carillo S; Bones J
J Pharm Biomed Anal; 2023 Sep; 234():115543. PubMed ID: 37385093
[TBL] [Abstract][Full Text] [Related]
36. Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
Jiang Y; Arora T; Klakamp S; Davis J; Chandrasekher YA; Young G; Du Y; Yu B; Miller KJ
Drugs R D; 2023 Dec; 23(4):377-395. PubMed ID: 37632627
[TBL] [Abstract][Full Text] [Related]
37. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
[TBL] [Abstract][Full Text] [Related]
38. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
[TBL] [Abstract][Full Text] [Related]
39. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
[TBL] [Abstract][Full Text] [Related]
40. Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis.
Kay J; Bock AE; Rehman M; Zhang W; Zhang M; Iikuni N; Alvarez DF
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36180101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]